A Pediatric Case Series of Autoimmune Lymphoproliferative Syndrome (ALPS): A Single-Center Experience
Journal of Human Immunity · 20.08.2026 · 2 (SGPI2026)
DOI: 10.70962/sgpi2026abstract.21 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Human Immunity, online erschienen am 20.08.2026. Verfasst von Nevenka Cigrovski und 12 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Autoimmune lymphoproliferative syndrome (ALPS) is an inborn error of immune dysregulation. A defect in lymphocyte apoptosis leads to their accumulation and the survival of autoreactive B lymphocytes. Main characteristics of the disease are lymphoproliferation (lymphadenopathy and/or organomegaly) and autoimmunity (primarily autoimmune cytopenias). There are clinical criteria for the diagnosis, and in most cases, genetic diagnosis is also possible (mutations in FAS, FASLG, and CASP10 genes). Some patients meet clinical criteria for ALPS, but genetic defects are still undetermined (ALPS-U). Material and Methods This is a descriptive study with an observational case series from the Department of Pediatrics at the University Hospital Centre Zagreb, Croatia. We reviewed medical records from January 2012 until February 2026 of eight patients with ALPS and analyzed their demographic, clinical, laboratory, genetic, and treatment data.
Results
Eight children (four males, four females) with ALPS are being followed up in our center. Median age at diagnosis was 5 years (range 4 months–11 years). The most common clinical manifestation was splenomegaly (87.5%), followed by autoimmune cytopenias (62.5%) and lymphadenopathy (37.5%). All patients had elevated double-negative T cells and vitamin B12. One patient had hypogammaglobulinemia. Five patients have identical mutations in the FAS gene (four heterozygous, one homozygous), one patient has a mutation in the FASLG gene, one patient has ALPS-U (mutation not found), and for one patient, genetic analysis is pending. Sirolimus was used in three patients, improving their blood counts and leading to regression of lymphadenopathy and splenomegaly, and was well tolerated.
Conclusion
Due to the variable penetrance and heterogeneous clinical presentation, ALPS should be considered even in cases with atypical manifestations. Timely diagnosis is important, especially in the presence of immune cytopenias, to make tailored treatment decisions. Genetic testing of family members is necessary due to the increased risk of developing lymphoma in all carriers of the mutation.
Zitieren
APA
Cigrovski, N., Pavlovic, M., Petrovic, A., Mucavac, L., Blekic, S. D., Salek, Z., Jakovljevic, G., Turudic, D., Todoric, I., Omerza, L., Vidakovic, M., Srsen, S., & Bilic, E. (2026). A Pediatric Case Series of Autoimmune Lymphoproliferative Syndrome (ALPS): A Single-Center Experience. Journal of Human Immunity, 2(SGPI2026). https://doi.org/10.70962/sgpi2026abstract.21
Vancouver
Cigrovski N, Pavlovic M, Petrovic A, Mucavac L, Blekic SD, Salek Z, et al. A Pediatric Case Series of Autoimmune Lymphoproliferative Syndrome (ALPS): A Single-Center Experience. Journal of Human Immunity. 2026;2(SGPI2026). doi:10.70962/sgpi2026abstract.21
BibTeX
@article{Cigrovski2026,
author = {Cigrovski, Nevenka and Pavlovic, Maja and Petrovic, Ana and Mucavac, Lucija and Blekic, Sara Dejanovic and Salek, Zrinko and Jakovljevic, Gordana and Turudic, Daniel and Todoric, Ivana and Omerza, Lana and Vidakovic, Marija and Srsen, Sasa and Bilic, Ernest},
title = {A Pediatric Case Series of Autoimmune Lymphoproliferative Syndrome (ALPS): A Single-Center Experience},
journal = {Journal of Human Immunity},
year = {2026},
volume = {2},
number = {SGPI2026},
doi = {10.70962/sgpi2026abstract.21}
}
EUVIMED